Prnewswireยท2025-10-08 12:02Core Insights - Hoth Therapeutics has expanded its AI initiative by securing annual NVIDIA AI Enterprise Essentials licenses to enhance its GPU-powered infrastructure for pharmaceutical research [1][2] - The integration of NVIDIA's AI platform is aimed at accelerating data-driven drug development and improving decision-making in therapy development [3] Company Strategy - The company is committed to integrating next-generation technology across its R&D programs, focusing on therapies like HT-001, HT-KIT, and oncology programs [3] - Hoth's AI initiative is part of a broader digital transformation strategy, enabling partnerships with AI-driven platforms and life-science data companies to optimize development timelines and reduce costs [3] Technological Capabilities - The NVIDIA AI Enterprise environment will support Hoth's scientific and data teams in deploying predictive pharmacology and toxicity models, enhancing compound screening efficiency [6] - The infrastructure will also facilitate the integration of multi-omic and patient-derived data for improved target discovery, clinical trial simulation, patient stratification, and real-time response monitoring [6]